Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This controlled multi-center randomized clinical trial, with direct individual benefit, will
compare efficacy and safety of two strategies in non-localized BP care: a combined regimen
using initial superpotent topical steroids associated with methotrexate for 4 weeks followed
by methotrexate alone for 8 months and superpotent topical steroids alone maintained 9 months
(current standard of care). The expected result is an equivalence between the two compared
strategies in terms of safety and efficacy, MTX monotherapy during the maintenance phase
being easier to manage and therefore associated with better compliance than topical steroids
with less cutaneous side effects and most cost-effective.